BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
CELL THERAPEUTICS (NQ: CTIC)
3.070 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 8:10 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(CTIC) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
71%
agree
7 votes
Waiting for FDA
60%
agree
5 votes
ctic fluk
0%
agree
0 votes
Lawsuits
April 21, 2014
(Value Investing, 5/1/12)
Stock symbols are the cornerstone of the stock market and a pure source of identity for companies. Billions of investment dollars change hands every day based on those little...(read more)
(Stock Blog Hub, 10/13/11)
In late September, Cell Therapeutics (CTIC) announced that a second independent radiologic review of data from the pivotal trial PIX301 of lead drug pixantrone for aggressive...(read more)
(Penny Stock DD, 10/4/11)
It's more than seven years since Cell Therapeutics Inc.'s (CTIC: News ) lead cancer drug Pixantrone has been under development. Rejected by the FDA in April 2010 after the...(read more)
Cell Therapeutics (CTIC) Company Overview

There is no analysis for CTIC yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here